Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.23%
#2 Pons Pons +35.07%
#3 TENDIES TENDIES +29.98%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.90%
#5 Starpower Starpower +28.39%
#6 StonkBroker StonkBroker +24.63%
#7 Mubarak Mubarak +24.35%
#8 SkyAI SkyAI +23.92%
#9 Hyperliquid Hyperliquid +20.74%
#10 PondCoin PondCoin +20.32%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Настройки
Язык
Pусский
Валюта
USD
Тема
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Ранг среди акций #28855
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Цена акции
$0.0578
Рыночная капитализация
$24.29M
Изменение (1 день)
1.40%
Изменение (1 год)
-27.93%
Страна
US
Торговля Provectus Biopharmaceuticals, Inc. (PVCT)

Категория

Healthcare
История дивидендов Provectus Biopharmaceuticals, Inc. (PVCT)
Provectus Biopharmaceuticals, Inc. (тикер: PVCT) выплатила в общей сложности 0 дивидендов.
Общая сумма всех дивидендов (с учетом дроблений акций): 0.00
Дивидендная доходность (TTM): 0
Дивидендные выплаты по Provectus Biopharmaceuticals, Inc. (PVCT) с 2026 по 2026
Годовые дивидендные выплаты
Год Дивиденды (с учетом дробления акций) Изменить
Недостаточно данных для указанных дат.
Список всех дивидендных выплат
Год Дивиденд Изменить
Недостаточно данных для указанных дат.
Дивиденды аналогичных компаний или конкурентов
Компания Количество дивидендных выплат Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH